Cobomarsen (MRG-106) is an oligonucleotide inhibitor of miR-155. Cobomarsen inhibits multiple gene pathways associated with cell survival (including JAK/STAT, MAPK/ERK and PI3K/AKT). Cobomarsen can be used for the research of B-cell lymphoma[1][2].
Cobomarsen (10 μM; 48-96 h) reduces cell proliferation and induces apoptosis in U2932, OCI-LY3, and RCK8 cells[2].Cobomarsen (10 μM; 72 h) significantly increases the expression of the four direct targets in the cell lines that overexpress miR-155[1].Cobomarsen (10 μM; 12 days) reduces cellular proliferation and induces apoptosis in MF and HTLV-1+ CTCL cells[1].Cobomarsen (10-50 μM; 7 days) reduces phosphorylation of the downstream signalling proteins AKT, ERK1/2, and STAT-3 in primary human activated T cells or MF cell lines[1].
Cobomarsen (1 mg/kg; i.v. on days 0, 2, 4, and 7) inhibits tumor growth in mice carrying U2932 cells xenografts[2].
[1]. Seto AG, et, al. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br J Haematol. 2018 Nov;183(3):428-444.
[2]. Anastasiadou E, et, al. Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo. Clin Cancer Res. 2021 Feb 15;27(4):1139-1149.